NICHE OF PRASUGREL AMONG OTHER PLATELET P2Y12-RECEPTOR INHIBITORS
https://doi.org/10.21518/2307-1109-2017-2-43-52
Abstract
Platelet P2Y12-receptor inhibitors are ranked 2nd in terms of administration frequency among antiplatelet agents (after acetylsalicylic acid). Administration of such drugs is mandatory in conditions characterized by increased activation of platelets, which, above all, include acute coronary syndrome and percutaneous coronary interventions. The use of clopidogrel, the most famous and commonly used today representative of P2Y12 receptor inhibitors, does not always result in reducing a risk of thrombotic complications.
The new generation representatives of the of P2Y12 receptor inhibitors (prasugrel, ticagrelor, cangrelor) showed their advantage over clopidogrel in the large-scale studies and are expected to improve the treatment situation not only in patients with acute coronary syndrome and after percutaneous coronary interventions, but also in other high-risk groups.
About the Authors
P. S. LAGUTA
National Medical Research Centre of Cardiology of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
E. P. PANCHENKO
National Medical Research Centre of Cardiology of the Ministry of Health of Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Мазуров А.В. Физиология и патология тромбоцитов. «Литтерра» 2011, 480 стр.
2. Kei AA, Florentin M et. al. Antiplatelet Drugs: What comes next? Clinical and Applied Thrombosis. Hemostasis, 2011, 17(1): 9-26.
3. Wiviott SD, Braunwald E et al. for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med., 2007, 357: 2001-2015.
4. Morrow DA, Wiviott SD et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation, 2009, 119: 2758-2764.
5. Wiviotti SD, Braunwald E et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind,randomised controlled trial. Lancet, 2009, 373: 723–31.
6. Wiviotti SD, Braunwald E et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet, 2008, 371: 1353–63.
7. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J., 2017, 00: 1–66.
8. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). 59p.
9. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2017, 0: 1–48.
10. Montalescot G, Bolognese L et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N. Engl. J. Med., 2013, 369: 999–1010.
11. Roe MT, Armstrong PW, Fox KA et al. Trilogy ACS Investigators. Prasugrel versus clopidogrel for the acute coronary syndromes without revascularisation. N. Engl. J. Med., 2012, 367(4): 1297-1309.
12. James SK, Roe MT, Cannon CP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient Outcomes (PLATO) Trial. Br. Med. J., 2011, 342: 3527.
13. Mauri L, Kereiakes DJ, Yeh RW et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Engl. J. Med., 2014, 371: 2155–2166.
14. Garratt KN, Weaver WD, Jenkins RG et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS LiberteЂpaclitaxeleluting coronary stent placement. Circulation, 2015, 131: 62–73.
15. Bonaca MP, Bhatt DL, Cohen M et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med., 2015, 372: 1791–1800.
Review
For citations:
LAGUTA P.S., PANCHENKO E.P. NICHE OF PRASUGREL AMONG OTHER PLATELET P2Y12-RECEPTOR INHIBITORS. Aterotromboz = Atherothrombosis. 2017;(2):43-52. (In Russ.) https://doi.org/10.21518/2307-1109-2017-2-43-52
Views:
1572
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 